Continuous Cardiac Output
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Nihon KohdenNEW YORK, NY
1 programCorrelation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver ResectionN/A
Heidelberg PharmaGermany - Ladenburg
1 programCorrelation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver ResectionN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Heidelberg PharmaCorrelation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection
Clinical Trials (1)
Total enrollment: 27 patients across 1 trials
NCT01443767Heidelberg PharmaCorrelation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection
Correlation of Estimated Continuous Cardias Output (esCCO) and Picco in Partial Liver Resection
Start: Jul 2011Est. completion: Nov 201127 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.